The TLC-ART team continues to advance long-acting, synchronized drug-combination therapy across HIV, anti-infective, and cancer research. Recent publications from the team and collaborators highlight progress in long-acting HIV injectable products, global access strategies for generic long-acting antiretrovirals, regulatory classification of long-acting parenteral products, and drug-combination nanoparticle approaches for cancer therapy.
Recent Publications
Long-acting all-in-one injectable TAF–dolutegravir–lamivudine
A novel all-in-one injectable composed of tenofovir alafenamide–dolutegravir–lamivudine exhibits long-acting plasma and cell drug persistence for 8 weeks
Stephen ZR, Perazzolo S, Duan L, Eguchi M, et al.
AIDS. 2026.
PMID: 42084126. DOI: 10.1097/QAD.0000000000004531.
View on PubMed →
This study reports a 3-in-1 long-acting injectable product composed of tenofovir alafenamide, dolutegravir, and lamivudine. The formulation is built on the drug-combination nanoparticle platform and was evaluated in juvenile nonhuman primates. The study showed long-acting plasma and cellular drug persistence for up to 8 weeks, supporting the potential of an all-in-one injectable HIV treatment approach.
CS-BLAP: classification system for long-acting parenteral products
Classification System Proposed to Guide the Design, Development, Regulatory Approval, and Scaling of Long-Acting, Small- and Macro-Molecule Parenteral Products (CS-BLAP)
Perazzolo S, Shen DD, Ho RJY.
Journal of Pharmaceutical Sciences. 2026;115(2):104056.
PMID: 41205697. DOI: 10.1016/j.xphs.2025.104056.
View on PubMed →
This article proposes CS-BLAP, a classification framework for long-acting parenteral products. The system is designed to guide product design, development, regulatory evaluation, and post-approval scaling. CS-BLAP distinguishes long-acting products based on product size, absorption route, lymphatic versus blood uptake, and whether the product is a small molecule or macromolecule.
Drug-combination nanoparticles for orthotopic breast tumor regression
Drug Combination Nanoparticles Containing Gemcitabine and Paclitaxel Enable Orthotopic 4T1 Breast Tumor Regression
Yu J, Xu X, Griffin JI, Mu Q, Ho RJY.
Cancers. 2024;16:2792.
DOI: 10.3390/cancers16162792.
View publication →
This study evaluated gemcitabine–paclitaxel drug-combination nanoparticles in an orthotopic 4T1 breast tumor model. The formulation enabled synchronized drug delivery and produced substantially greater tumor suppression than equivalent free-drug combination treatment, supporting the broader application of the DcNP platform in cancer therapy.
Orthotopic Pan02 pancreatic tumor model
Inoculation of Pan02 Cells Produces Tumor Nodules in Mouse Pancreas: Characterization of a Novel Orthotopic Pancreatic Ductal Adenocarcinoma Tumor Model for Interventional Studies
Griffin JI, Chen X, Duan L, Mu Q, Ho RJY.
PLOS ONE. 2024;19(3):e0300723.
DOI: 10.1371/journal.pone.0300723.
View publication →
This work describes a reproducible orthotopic pancreatic ductal adenocarcinoma model using intraperitoneal inoculation of Pan02 cells in mice. The model produces pancreatic tumor nodules without surgical implantation, providing a practical preclinical platform for evaluating pancreatic cancer treatment candidates.
Drug-combination nanoparticles for metastatic breast cancer
Novel Drug Combination Nanoparticles Exhibit Enhanced Plasma Exposure and Dose-Responsive Effects on Eliminating Breast Cancer Lung Metastasis
Mu Q, Yu J, Griffin JI, Wu Y, Zhu L, McConnachie LA, Ho RJY.
PLOS ONE. 2020;15(3):e0228557.
DOI: 10.1371/journal.pone.0228557.
View publication →
This study demonstrated that gemcitabine–paclitaxel drug-combination nanoparticles increased drug exposure and showed dose-responsive activity against breast cancer lung metastasis in a mouse model. The findings support the DcNP platform as a scalable approach for improving combination chemotherapy delivery.
About TLC-ART
TLC-ART develops targeted, long-acting, synchronized drug-combination therapies designed to improve drug exposure at relevant tissues and cells while reducing limitations associated with conventional dosing. The program applies drug-combination nanoparticle technologies across HIV, anti-infective, and cancer applications.
Contact: tlc-art@uw.edu